301 (PB081) - The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds

Abstract

Background: One of the major causes of failure to achieve cure in cancer patients is the development of resistance to the drugs after an initial response. EG-011 is the first-in-class Wiskott-Aldrich syndrome protein (WASP) activator (Spriano et al, AACR 2022) with anti-tumor activity in hematological cancers (Gaudio et al, AACR 2019). Here, we assessed EG-011 in the context of cellular models of secondary resistance to FDA approved agents: marginal zone lymphoma (MZL) cell lines resistant to PI3K and BTK inhibitors and multiple myeloma (MM) cell lines resistant to proteasome inhibitors.